The acquisition will bring together ImmunoVaccine Technologies (IVT’s) signature VacciMax platform with Immunotope’s portfolio of immunotherapeutic antigens and antigen discovery platform, allowing the new private company to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. The combined clinical-stage company will continue to support Immunotope’s ongoing Phase I immunotherapeutic vaccine clinical trial in ovarian and breast cancer patients at Duke University Comprehensive Cancer Center.
Randal Chase, president and CEO of IVT, said: “With this acquisition, we enhance our research capabilities, expand our operations into the US and gain a distinct competitive advantage for our immunotherapy products.”